Lucio Loreggian
About
In The Last Decade
Lucio Loreggian
15 papers receiving 341 citations
Peers
Comparison fields: 5 of 40
- Pulmonary and Respiratory Medicine 311
- Radiology, Nuclear Medicine and Imaging 72
- Surgery 51
- Oncology 44
- Molecular Biology 36
Countries citing papers authored by Lucio Loreggian
This map shows the geographic impact of Lucio Loreggian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucio Loreggian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucio Loreggian more than expected).
Fields of papers citing papers by Lucio Loreggian
This network shows the impact of papers produced by Lucio Loreggian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucio Loreggian. The network helps show where Lucio Loreggian may publish in the future.
Co-authorship network of co-authors of Lucio Loreggian
This figure shows the co-authorship network connecting the top 25 collaborators of Lucio Loreggian. A scholar is included among the top collaborators of Lucio Loreggian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucio Loreggian. Lucio Loreggian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 2 | |
| 3 | 17 | |
| 4 | 3 | |
| 5 | Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). | 6 |
| 6 | 17 | |
| 7 | 15 | |
| 8 | 8 | |
| 9 | 1 | |
| 10 | Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. | 18 |
| 11 | 55 | |
| 12 | 105 | |
| 13 | 91 | |
| 14 | 4 | |
| 15 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.